Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471624 · ClinicalTrials.gov registry record · Phase 4
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 270
- Enrollment target
NCT03471624: Completed Phase 4 study, sponsored by Stanford University.
NCT03471624 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 270 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03471624, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 270 participants
- Enrollment target
Study Summary
Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment
Interventions
- DRUG Tenofovir Alafenamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2022-04-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03471624
The ClinicalTrials.gov registry entry for NCT03471624 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir Alafenamide is the first listed.
NCT03471624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03471624 about?
NCT03471624 is a clinical study titled "Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)". Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment
What is the current status of trial NCT03471624?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 270 participants. The study started on 2018-05-01. Estimated completion is 2022-04-19.
What interventions are being tested in trial NCT03471624?
The interventions under investigation include: Tenofovir Alafenamide (DRUG).
Who is sponsoring clinical trial NCT03471624?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.